Puma Biotechnology Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology or view top-rated stocks.

Wall Street analysts have given Puma Biotechnology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Puma Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Puma Biotechnology.

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.11. The biopharmaceutical company earned $98.20 million during the quarter, compared to the consensus estimate of $74.55 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 318.22% and a negative net margin of 9.77%. The company's revenue for the quarter was up 91.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.43) earnings per share.
View Puma Biotechnology's earnings history.

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PBYI stock has increased by 6.6% and is now trading at $9.88.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1-year target prices for Puma Biotechnology's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Puma Biotechnology's stock price to reach $11.50 in the next year. This suggests a possible upside of 16.4% from the stock's current price.
View analysts' price targets for Puma Biotechnology or view top-rated stocks among Wall Street analysts.

Some companies that are related to Puma Biotechnology include Y-mAbs Therapeutics (YMAB), NGM Biopharmaceuticals (NGM), Amneal Pharmaceuticals (AMRX), Indivior (INVVY), PMV Pharmaceuticals (PMVP), Cytokinetics (CYTK), Heron Therapeutics (HRTX), uniQure (QURE), PureTech Health (PRTC), Kura Oncology (KURA), Prelude Therapeutics (PRLD), COMPASS Pathways (CMPS), Design Therapeutics (DSGN), Stoke Therapeutics (STOK) and Avid Bioservices (CDMO).
View all of PBYI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Deerfield Management Company L.P. Series C (9.34%), Fred Alger Management LLC (8.99%), BlackRock Inc. (7.68%), Renaissance Technologies LLC (3.94%), Palo Alto Investors LP (3.45%) and Acadian Asset Management LLC (3.01%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deerfield Management Company L.P. Series C, BNP Paribas Arbitrage SA, Ikarian Capital LLC, Renaissance Technologies LLC, Bank of Montreal Can, Credit Suisse AG, and Jupiter Asset Management Ltd.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, and Richard Paul Bryce.
View insider buying and selling activity for Puma Biotechnology or view top insider-selling stocks.

PBYI stock was purchased by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Worth Venture Partners LLC, Fred Alger Management LLC, Citigroup Inc., Goldman Sachs Group Inc., Envestnet Asset Management Inc., BlackRock Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for Puma Biotechnology or or view top insider-buying stocks.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBYI stock can currently be purchased for approximately $9.88.

Puma Biotechnology has a market capitalization of $398.78 million and generates $225.10 million in revenue each year. The biopharmaceutical company earns $-59,990,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

Puma Biotechnology employs 267 workers across the globe.

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Puma Biotechnology is headquartered at 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]